ADL Bionatur Solutions

  • Land: Spanien

Nachricht vom 07.08.2019 | 09:15


DGAP-News: ADL Bionatur Solutions / Key word(s): Alliance

07.08.2019 / 09:15
The issuer is solely responsible for the content of this announcement.


- Alliance reaffirms ADL as global supply partner of sterile active pharmaceutical ingredients
- Revenues of initial EUR 13 Million over the next 5 years
- ADL extends its client base in Asia-Pacific
- Strong guidance for financial year 2019 confirmed

León, Spain, 07 August 2019 - ADL Bionatur Solutions (MAB: ADL), a company specialized in research and development of health, cosmetic and beauty products, services and industrial fermentation production, announced today the signing of a strategic alliance with a new customer in Japan for active sterile pharmaceutical ingredients (APIs) production. The revenues of the contract with the undisclosed Manufacturer of pharmaceuticals, agricultural chemicals and veterinary drugs amounts to an initial amount of EUR 13 million over the next 5 years.

"We are delighted to win a leading Japanese pharma company as a new customer for our API production. This 5-year partnership underlines our claim and commitment to high-quality APIs production in sterile conditions. ADL is broadening its customer base in Asia-Pacific ensuring access to the fast-growing market of this region," said Pilar de la Huerta, CEO of ADL Bionatur Solutions. "The previously announced contract extensions and this new alliance keep us right on track for our strong financial guidance to achieve an overall positive EBITDA full year results as well as revenues between EUR 50 - 55 million."

ADL holds foreign manufacturer accreditations (FMA) from the PMDA (Pharmaceuticals and Medical Devices Agency of Japan) and MFDS (Ministry of Food and Drug Safety of South Korea), within others, and is an established partner for APIs production under sterile condition worldwide.

About ADL Bionatur Solutions
ADL Bionatur Solutions (MAB: ADL) is a company specialized in biopharma manufacturing plus research and development targeting the human microbiome and the animal health sector. The Company, that owns the largest fermentation production plant in Southern Europe, carries out high value-added product development, scale-up and production for third parties. International healthcare companies as well as first-in-class academic and industrial laboratories mainly from Europe and the US are part of ADL's customer base. The biopharma manufacturing business is complemented by a research and development division, which creates a proprietary product pipeline in animal and human health. ADL is listed on the MAB, Spain's Alternative Stock Market (ISIN ES0184980003) and its major shareholder is the investment fund Black Toro Capital holding 73%. More information is available at

For more Information please contact:

ADL Bionatur Solutions
Blanca San Román
IRO and Communications

International Media & Investor Relations
MC Services
Raimund Gabriel
Tel.: +49 89 21022880

07.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Interview im Fokus

„Im europäischen Spitzenfeld der Private-Equity-Liga“

Die Münchner Private-Equity-Gesellschaft Mutares (ISIN: DE000A2NB650) ist mit bereits fünf Akquisitionen in 2020 erneut mit einem hohen Wachstumstempo unterwegs. Im Exklusivinterview mit verraten die Vorstände Robin Laik (CEO) und Johannes Laumann (CIO), wie man sich bei den jüngsten Deals gegen die Konkurrenz durchgesetzt hat, wie man einen Return auf das eingesetzte Kapital von 7 bis 10 erreichen will und warum sich Mutares-Aktionäre auch für 2020 auf eine attraktive Dividende freuen dürfen.

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.


Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.

News im Fokus

HeidelbergCement AG: Vorläufiges Ergebnis von HeidelbergCement im zweiten Quartal 2020 über Markterwartungen

14. Juli 2020, 16:38

Aktuelle Research-Studie

Original-Research: German Real Estate Capital S.A. (von GBC AG): Management Interview German Real Estate Capital S.A.

14. Juli 2020